Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692

Diabetes Care. 2017 Apr;40(4):e47-e48. doi: 10.2337/dci16-0048.

Affiliations

¹ Yale School of Medicine, New Haven, CT silvio.inzucchi@yale.edu.
² Yale School of Medicine, New Haven, CT.
³ Alpert Medical School of Brown University, Providence, RI.
⁴ Vermont College of Medicine, Burlington, VT.
⁵ University of Tennessee Health Science Center, Memphis, TN.
⁶ Case Western Reserve University and VA Medical Center, Cleveland, OH.
⁷ University of Pittsburgh School of Medicine, Pittsburgh, PA.
⁸ Florida Hospital, Orlando, FL.
⁹ VA Medical Center and University of Colorado School of Medicine, Denver, CO.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Cerebrovascular Disorders
Diabetes Mellitus, Type 2
Humans
Hyperglycemia
Hypoglycemic Agents
Insulin
Insulin Resistance*
Pioglitazone
Thiazolidinediones*

Substances

Hypoglycemic Agents
Insulin
Thiazolidinediones
Pioglitazone

Grants and funding

U01 NS044876/NS/NINDS NIH HHS/United States